Loading...
•
Mar 31, 2023
United Therapeutics Q1 2023 Earnings Report
United Therapeutics reported a revenue increase of 10% year-over-year, reaching $506.9 million, driven by the strength of the Tyvaso franchise and record revenues from Orenitram.
Key Takeaways
United Therapeutics Corporation announced its Q1 2023 financial results, with total revenues growing 10% year-over-year to $506.9 million. The company's performance was driven by the Tyvaso franchise and record revenues from Orenitram. Net income remained relatively flat at $240.9 million compared to $239.9 million in the same quarter of the previous year.
Total revenues increased by 10% year-over-year, reaching $506.9 million.
Tyvaso sales increased by 39% year-over-year, driven by Tyvaso DPI and label expansion.
Orenitram achieved record revenues in the first quarter.
Clinical team continues to progress four registration studies.
Revenue by Segment
Forward Guidance
The company is focused on sustaining its mission to help patients in need and progressing its clinical trials and research and development plans.
Positive Outlook
- Developing novel pharmaceutical therapies
- Expanding the availability of transplantable organs
- Innovating for unmet medical needs of patients
- Benefiting other stakeholders
- Providing superior financial performance for shareholders
Challenges Ahead
- Risks and uncertainties described in periodic reports filed with the SEC
- Factors that could cause actual results to differ materially from anticipated results
- Cautionary statements and risk factors set forth in periodic reports and documents filed with the SEC
- Most recent Annual Report on Form 10-K
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...